Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cell cycle checkpoint/DNA repair antagonist IC83

A proprietary agent with potential antineoplastic activity. IC83 appears to target cell cycle checkpoint/DNA repair enzymes, which are involved in the recognition and repair of damaged DNA and are overexpressed in many types of cancer cells. Inhibition of cell cycle checkpoint/DNA repair enzymes may enhance the cytotoxicity of DNA damaging agents and dissipate tumor cell resistance to chemotherapy and radiation therapy.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	IC83

cell cycle checkpoint/DNA repair antagonist IC83

Search NCI's Drug Dictionary